¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼­¿ï´ëÇб³ Ä¡°úº´¿ø 2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2019-07-12

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼­¿ï´ëÇб³ Ä¡°úº´¿ø 2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2019-07-12
±³À°ÀÏÀÚ : 2019-07-12
±³À°Àå¼Ò : ¼­¿ï´ëÇб³ Ä¡°úº´¿ø 8Ãþ °­´ç  
±³À°ÁÖÁ¦ : 2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇìÁø
¿¬¶ôó : 02-516-6581  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-12 °­´ç 10:00~10:30 Overview of cellular immunotherapy for cancer  ±èűÔ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 10:30~11:00 Development of a new platform for T cell immunotherapy: Avidity control of T-cell antigen receptor and adhesion receptors  Àüâ´ö(GIST) 
±³À°½Ã°£ 07-12 °­´ç 11:00~11:30 Evolution of CAR-T therapy  ±èÂùÇõ(KAIST) 
±³À°½Ã°£ 07-12 °­´ç 11:30~12:00 Recent advances in cell reprogramming and gene targeting as new therapies for neurodegenerative disease  ±èÁ¾ÇÊ(µ¿±¹´ë) 
±³À°½Ã°£ 07-12 °­´ç 13:00~13:30 Natural killer cell therapy and monoclonal antibodies  Á¶´ö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 13:30~14:00 Recent advances of CAR-T cell therapy in lymphoma/myeloma  À±´öÇö(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 14:00~14:30 Real-world experiences of CAR T cell therapy in pediatric ALL: efficacy and toxicity  °í°æ³²(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 14:30~15:00 Mesenchymal stem cells in hematopoietic stem cell transplantation  À¯°ÇÈñ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 15:20~15:50 Clinical & immunological evaluation of cellular immunotherapy in cancer patients  È²À¯°æ(GC³ì½ÊÀÚ·¦¼¿) 
±³À°½Ã°£ 07-12 °­´ç 15:50~16:20 Clinical trial of dendritic cell therapy with immunomodulating agents in myeloma  Á¤¼ºÈÆ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 07-12 °­´ç 16:20~16:50 Clinical trial design for cellular immunotherapy  ¾Èº´Áø(¾¾¾Ø¾Ë¸®¼­Ä¡) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼­¿ï´ëÇб³ Ä¡°úº´¿ø 2019 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2019-07-12""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2019 ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2019-07-12
´ÙÀ½±Û ´ëÇÑ¿µ»óÀÇÇÐȸ 2019 Àü°øÀÇ ¿¬¼ö±³À° ÀǷ῵»ó Ç°Áú°ü¸® Á¦ 1ºÎ : 2019-07-12
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20664 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-05-28 0 28 2024-05-10
20663 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦1ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-05-27 0 26 2024-05-10
20662 ¼­¿ï ´ëÇѿ°èÁٱ⼼Æ÷Àç»ýÀÇÇÐȸ - Á¦20ȸ Ãá°èÇмú´ëȸ (ÇÏÀ̺긮µå) : 2024-05-26 0 19 2024-05-10
20661 ºÎ»ê ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ºÎ¿ï°æÁöȸ 5¿ù ¿¬¼ö°­Á : 2024-05-26 0 16 2024-05-10
20660 ¼­¿ï ´ëÇѽŰæ±Ù°ñ°áÃÊÀ½ÆÄÇÐȸ Á¦1ȸ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-05-25 0 24 2024-05-10
20659 ´ëÀü ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-´ëÀüÃæ³² : 2024-05-25 0 10 2024-05-10
20658 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-25 0 15 2024-05-10
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 14 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 19 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 7 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 13 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 14 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 20 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 19 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 6 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷